Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 33-38

  Shimada, Muneaki ^a   Fujiwara, Hiroyuki ^b   Sato, Shinya ^a   Oishi, Tetsuro ^a   Itamochi, Hiroaki ^a   Machida, Shizuo ^b   Takei, Yuji ^b   Harada, Tasuku ^a   Suzuki, Mitsuaki ^b   Kigawa, Junzo ^c  

^a TOTTORI UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

AUC; Chemotherapy; CPT 11; Nedaplatin; Phase I study

Indexed keywords

CREATININE; IRINOTECAN; NEDAPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VAGINA CANCER; VOMITING; VULVA CANCER;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; GENITAL NEOPLASMS, FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; NAUSEA; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS;

EID: 84863479426     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1885-z     Document Type: Article

References (22)

1. Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T (2007) Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Cancer Chemother Pharmacol 59:575-580 (Pubitemid 46295121)
2. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) An early phase II clinical study of cis-diammine glycolato platinum, 254-s, for head and neck cancers. Jpn J Cancer Chemother 19:863-869
3. Furuse K, Gukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, Kimura I, Inoue S, Yoshima S, Kusume K, Sugimoto K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for plimary lung cancer. Jpn J Cancer Chemother 19:879-884
4. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T, Hirabayashi K, Yamabe T, Hatae M (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19:885-892
5. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58:31-37 (Pubitemid 30045307)
6. Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M (2003) Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102-107 (Pubitemid 37025968)
7. Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N, Negoro S (2004) Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032-1037 (Pubitemid 39336239)
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756 (Pubitemid 19272848)
9. Chatelut E, Canal P, Brunner V, Chevreau C, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580
10. Sasaki Y, Tamura T, Taguchi K, Shinka T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijyo N (1989) Pharmacokinetics of (glycolato-O,O′)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243-246 (Pubitemid 19093746)
11. Ishibashi T, Yano Y, Oguma T (2002) A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50:230-236 (Pubitemid 35013661)
12. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56:205-213 (Pubitemid 36981436)
13. Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K (2009) Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep 21:1005-1009
14. Sato S, Fujiwara H, Oishi T, Shimada M, Machida S, Takei Y, Itamochi H, Suzuki M, Kigawa J (2012) Evaluation of a formula for individual dosage of nedaplatin based on renal function. Cancer Chemother Pharmacol 69:599-603
15. Ishibashi T, Yano Y, Oguma T (2005) Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxycodynamic analysis. Anticancer Res 25:1273-1281 (Pubitemid 40546802)
16. Ikeuchi I, Daikatsu K, Fujisawa I, Amano T (1990) Determination of platinum in biological materials by graphic furnace atomic absorption spectrometry. Iyakuhin Kenkyu 21:1082-1087
17. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854 (Pubitemid 28096082)
18. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725 (Pubitemid 24241187)
19. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388 (Pubitemid 41103619)
20. Matsumura M, Takeshima N, Ota T, Omatsu K, Sakamoto K, Kawamata Y, Umayahara K, Tanaka H, Akiyama F, Takizawa K (2010) Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy. Gynecol Oncol 119:212-216
21. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28. Pharmacogenet Genomics 17:497-504 (Pubitemid 46905216)
22. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 33:161-183 (Pubitemid 27399545)